Gates Foundation Funds Surveillance of Anti-Vaccine Groups

Gates Foundation Funds Surveillance of Anti-Vaccine Groups







Sayer Ji, Contributor
Activist Post

The Bill & Melinda Gates foundation launched the Grand Challenges in Global Health (GCGH) in partnership with the National Institutes of Health in 2003 which, according to the GCGH website,
is aimed at "creating new tools that can radically improve health in
the developing world." So far, 45 grants totaling $458 million were
awarded for research projects involving scientists in over 30 countries.
[1]

But where has all the money actually gone? Towards developing and
implementing water purification and sanitation systems? Or basic
nutritional support aimed at optimizing immune function? How about
providing shelter and medical facilities for the homeless? Not even close.

For example, a $100K grant was recently disbursed to Seth C. Kalichman,
professor at the Department of Psychology, University of Connecticut,
for "Establishing an Anti-Vaccine Surveillance and Alert System," which
intends to "establish an internet-based global monitoring and rapid
alert system for finding, analyzing, and counteracting misinformation communication campaigns regarding vaccines to support global immunization efforts." [emphasis added]

We can only wonder what organizations might be labeled as
"misinformation communication campaigns" considering the fact that Bill
Gates, in a Feb. 4th, 2011 interview on CNN with Sanjay Gupta said that
"anti-vaccine groups 'kill children.'" Here is the full quote:
<blockquote class="tr_bq">So it's an absolute lie
that has killed thousands of kids. Because the mothers who heard that
lie, many of them didn't have their kids take either pertussis or
measles vaccine, and their children are dead today. And so the people
who go and engage in those anti-vaccine efforts -- you know, they, they
kill children. It's a very sad thing, because these vaccines are
important.</blockquote>
It is quite possible that any dissenting voice not in support of
universal vaccination campaigns may be included in this type of
"surveillance and alert system" as a potentially endangering the lives
of others, i.e. "killing children." What is so ironic about the
situation is that the Gates Foundation-supported Polio Global Eradication Initiative may have resulted in over 47,500 cases of vaccine-induced paralysis
in Indian children in 2011 alone, and which is twice as deadly as the
wild-type polio it claimed to have put an end to officially on Jan. 11
2012. Who here then, is truly concerned about the health of children?

Moreover, it is exceedingly difficult to view Bill & Melinda Gates
foundation's GCGH as a strictly humanitarian foundation considering many
of the projects it chooses to fund. Here are a few listed on their website which have already received funding.

• Synthetic Lymph Nodes: Steven Meshnick and Carla Hand of
  the University of North Carolina in the U.S. will develop a
  bio-compatible, biodegradable polymer device that can be placed under
  the skin to introduce vaccines and antigens to the immune system. The
  device will attract immune cells and trigger their proliferation as well
  asact as an adjuvant at the site of injection. If successful, the
  device could help boost immune response to new and existing vaccines.
  [see our article on transhumanistic technologies].
  

• Needle Free Vaccination Via Nanoparticle Aerosols: Vaccine
  delivery systems that target specific areas of the body have the
  potential to be especially effective against some types of infection.
  For example, inhaled vaccines may better guard against respiratory
  diseases, such as tuberculosis, and those that commonly infect the
  tissues of the nose and throat, such as diphtheria. Dr. Edwards is
  leading a multidisciplinary team using materials science technologies
  combined with infectious disease, device, and toxicology expertise to
  reformulate tuberculosis and diphtheria vaccines into aerosol sprays
  that can be inhaled. The team's ultimate objective is to develop a
  cell-based BCG vaccine for tuberculosis and a protein antigen CRM 197
  vaccine for diphtheria in the form of novel porous nanoparticle
  aggregate (PNAP) aerosols.
  

• Plant-Produced Synthetic RNA Vaccines: Alison
  McCormick of Touro University, California in the U.S. will test the
  ability of a low-cost plant-based synthetic biology method to produce a
  combined viral protein epitope with an antigen RNA expression system for
  use in an RNA malaria vaccine. Using plants for this viral transfection
  system could make RNA vaccine production scalable and cost effective.
  

• Profitable Vaccine Distribution In Emerging Markets: Lisa
  Ganley-Leal and Pauline Mwinzi of Epsilon Therapeutics, Inc. in the U.S.
  will test the hypothesis that selling vaccines through medicine shops
  in emerging markets can lead to profits for both vaccine developers and
  the small business owners. Demonstrating profitability may lead
  pharmaceutical companies to invest greater resources in vaccine
  development and distribution and develop local partnerships for
  profitability strategies.
  

• Genetically Programmed Pathogen Sense and Destroy: Saurabh
  Gupta and Ron Weiss of Massachusetts Institute of Technology in the U.S.
  proposed creating sentinel cells that can detect the presence of a
  pathogen, report its identity with a biological signal, and secrete
  molecules to destroy it. This project's Phase I research demonstrated
  that commensal bacteria can be engineered to detect and specifically
  kill the model bacterial pathogen Pseudomonas aeruginosa. In Phase II,
  Gupta and Weiss will engineer the human microbiota to specifically
  detect and destroy the gut pathogen Shigella flexneri, which is
  responsible for high mortality rates in children.
  

• Vaccine in a Salt Shaker: A New, Safe, Low-Cost Approach:
  Shiladitya DasSarma will lead a team at the University of Maryland,
  Baltimore in the U.S. to develop an inexpensive, safe, and effective
  oral vaccine against invasive Salmonella disease using gas-filled
  bacterial vesicles. The project seeks to produce a salt-encased,
  shelf-stable vaccine requiring no refrigeration for distribution
  worldwide.
  

• A Humanized Mouse Model to Evaluate Live Attenuated Vaccine Candidates:
  To develop new vaccines against some of the world's biggest killers,
  including HIV, malaria, and tuberculosis, scientists must be able to
  evaluate promising candidates. Some of the most promising potential
  vaccines, are made from weakened live versions of the infectious agent.
  As a result, they cannot be studied in human trials unless researchers
  can be confident that the weakened vaccines will be safe. Dr. Flavell
  and his colleagues are working to genetically engineer laboratory mice
  whose immune systems are similar enough to humans to permit testing of
  vaccines against diseases that disproportionately affect people in the
  developing world.
  

• Alternative Delivery of Human Milk Proteins to Infants: Qiang
  Chen of Arizona State University in the U.S. proposes to engineer
  edible plants, such as lettuce and rice, to express beneficial proteins
  found in human milk. The protein bodies in these plants allow for the
  stable, high accumulation of these human milk proteins, and the plants
  can either be eaten directly by infants or formulated into baby food to
  provide essential nutrients and antibacterial benefits.
  

• Non-Hormonal Female Contraceptive Targeting Egg-Specific Metalloprotease: John
  Herr of the University of Virginia in the U.S. will research the
  egg-specific membrane enzyme metalloprotease as a target for a
  non-hormonal female contraceptive. After determining the nature of the
  enzyme's catalytic pocket, a family of peptidomimetic compounds will be
  tested for their ability to bind to the enzyme and block its key role in
  egg fertilization.
  

• Bacillus-Fermented Natto as Edible Vaccines for the Developing World: Michael
  Chan of the Ohio State Research Foundation in the U.S. will develop an
  engineered strain of bacteria used to ferment beans in traditional Asian
  and African diets, to display an antigen from the Tuberculosis
  bacterium. The engineered bacillus will then be used to make the
  traditional Asian dish natto, which can serve as a kind of oral vaccine
  to elicit a strong immune response. If successful, this strategy can be
  used to introduce a variety of disease antigens through culturally
  accepted foods.
  

• Nanotechnology-Based Contraception: David Clapham of
  Children's Hospital Boston in the U.S. will develop and test a
  nanoparticle contraceptive that releases sperm tail inhibitors in
  response to vaginal pH changes or exposure to prostatic fluid. If
  successful, the nanoparticles could be incorporated into a vaginal gel
  to block sperm motility required for fertilization.
  

• Circumcision tool For Traditional Ceremonies In Africa: Kathleen
  Sienko of the University of Michigan in the U.S. has developed a
  prototype circumcision tool for use in traditional ceremonies in Africa,
  and seeks to demonstrate the functionality, cultural suitability, and
  potential for low-cost mass production of the device. Such a tool could
  increase the circumcision rates leading to lower rates of HIV
  transmission in the region.
  

• Discovery of Chemosensory Molecules as Novel Contraceptives: John
  Ngai and Scott Laughlin of the University of California, Berkeley in
  the U.S. seek to identify chemical compounds in the female reproductive
  system that guide sperm cells to the egg. By characterizing these
  "odorants," synthetic versions can be produced and administered to
  disrupt this navigation system thus inhibiting fertilization.
  

• Transgenic Cow Milk Containing Human Antimicrobial Protein:
  Hironori Matsushima of the University of Toledo in the U.S. will test
  the hypothesis that adding an antimicrobial peptide to powdered milk
  products can confer protection against enteric diseases. Research will
  focus on testing the peptide for its ability to kill pathogens in
  stomach conditions, and on its ability to maintain integrity through the
  milk pasteurization and drying processes.
  

• Ultrasound as a Long-Term, Reversible Male Contraceptive: James
  Tsuruta and Paul Dayton of the University of North Carolina, Chapel
  Hill will study the ability of therapeutic ultrasound to deplete
  testicular sperm counts. Characterizing the most beneficial timing and
  dosage could lead to the development of a low-cost, non-hormonal and
  reversible method of contraception for men.
  

You will notice from the examples listed above that all of these
funded projects involve the development of proprietary (read:
potentially profitable) and as-of-yet unproven technologies, and which
will require the transformation and/or alteration of a natural process
or substance. Also, many of the grant disbursements have gone towards
contraception. This appears to diverge from the GCGH's mission statement
of "improving health in the developing world," insofar as it is focused
on reducing population in the developed world, rather than supporting
the health of those already living, in need of help.


Source:-
http://www.activistpost.com/2012/08/gates-foundation-funds-surveillance-of.html